Management of Daytime Aggressive Behaviors in Dementia Patients

Introduction to Guidelines

The American Geriatrics Society recommends that for daytime aggressive behaviors in dementia patients on trazodone, systematic non-pharmacological interventions should be implemented while investigating reversible medical causes, and if behaviors remain severe, an SSRI should be initiated as first-line pharmacological treatment 1

Pain assessment is the highest priority, as untreated pain is a major contributor to behavioral disturbances, and must be addressed before considering psychotropic adjustments 1, 2
The American College of Physicians suggests checking for urinary tract infections and pneumonia, which are common triggers of agitation 1
Evaluate for constipation, urinary retention, and dehydration, as these can also contribute to aggressive behavior 1
Review all medications to identify and discontinue anticholinergic agents that worsen confusion and agitation 1
Assess for sensory impairments that increase confusion and fear 1

The American Geriatrics Society recommends using calm tones, simple one-step commands, and gentle touch for reassurance, rather than complex multi-step instructions 1, 2
Allow adequate time for the patient to process information before expecting a response 1
Avoid confrontational approaches that escalate resistance 2
Ensure adequate lighting and reduce excessive noise 1
Provide predictable daily routines with structured activities 1
Use ABC charting to identify specific triggers of aggressive behavior 1
Install safety equipment and remove hazardous items 1
Engage in activities tailored to individual abilities and previous interests 3
Ensure at least 30 minutes of supervised mobility and sunlight exposure daily 1

If non-pharmacological interventions fail, initiate an SSRI as first-line pharmacological treatment for chronic agitation, with citalopram starting at 10 mg/day and sertraline starting at 25-50 mg/day 1
SSRIs significantly reduce overall neuropsychiatric symptoms, agitation, and depression in dementia patients, with a substantially better safety profile than antipsychotics 1
Antipsychotics should only be used when the patient is severely agitated and threatening substantial harm to self or others, and behavioral interventions plus SSRI trial have failed, with risperidone starting at 0.25 mg once daily at bedtime 1
The American Psychiatric Association recommends avoiding benzodiazepines for routine agitation management, as they increase delirium incidence and duration, cause paradoxical agitation, and worsen cognitive function 1
Avoid typical antipsychotics as first-line therapy, as they are associated with a high risk of tardive dyskinesia 1

Evaluate response to SSRIs within 4 weeks using quantitative measures, and monitor for side effects including nausea, sleep disturbances, and falls 1
Use the lowest effective dose of antipsychotics for the shortest possible duration, and evaluate ongoing need daily with in-person examination 1
Attempt taper within 3-6 months to determine the lowest effective maintenance dose, and monitor for extrapyramidal symptoms, falls, metabolic changes, QT prolongation, and cognitive worsening 1

The Neuropsychiatric Inventory Questionnaire (NPI‑Q) should be employed to quantify baseline severity of aggressive and other neuropsychiatric symptoms in individuals with dementia and to provide an objective measure for monitoring response to interventions. 4
The same recommendation is supported by an additional source, reinforcing the use of the NPI‑Q for baseline assessment and ongoing evaluation of behavioral disturbances in dementia patients. 5